Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor, dose-dependently reduces the expression of extremely long genes in mouse and human neurons, including nearly all genes that are longer than 200 kilobases. Expression of long genes is also reduced after knockdown of Top1 or Top2b in neurons, highlighting that both enzymes are required for full expression of long genes. By mapping RNA polymerase II density genome-wide in neurons, we found that this length-dependent effect on gene expression was due to impaired transcription elongation. Interestingly, many high-confidence ASD candidate genes are exceptionally long and were reduced in expression after TOP1 inhibition. Our findings suggest that chemicals and genetic mutations that impair topoisomerases could commonly contribute to ASD and other neurodevelopmental disorders.
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor, dose-dependently reduces the expression of extremely long genes in mouse and human neurons, including nearly all genes that are longer than 200 kilobases. Expression of long genes is also reduced after knockdown of Top1 or Top2b in neurons, highlighting that both enzymes are required for full expression of long genes. By mapping RNA polymerase II density genome-wide in neurons, we found that this length-dependent effect on gene expression was due to impaired transcription elongation. Interestingly, many high-confidence ASD candidate genes are exceptionally long and were reduced in expression after TOP1 inhibition. Our findings suggest that chemicals and genetic mutations that impair topoisomerases could commonly contribute to ASD and other neurodevelopmental disorders.
Autism is a neurodevelopmental disorder with symptoms that include repetitive behaviours and deficits in social interactions. Hundreds of genes are now associated with ASD 1,2 , suggesting that there are diverse genetic risk factors for autism. Environmental factors, including chemicals that are ingested during critical periods of brain development 3 , can also increase autism risk. Many ASD candidate genes regulate synapse function [4] [5] [6] ; however, whether there are additional mechanisms that unite ASD patients or expression of ASD genes is unclear.
Recently, we found that topoisomerase inhibitors can transcriptionally un-silence the paternal allele of Ube3a in mouse cortical neurons 7 . Ube3a is located adjacent to a cluster of imprinted genes, is normally expressed only from the maternal allele in neurons, and regulates synaptic function 8 . In humans, UBE3A is associated with two distinct neurodevelopmental disorders. Specifically, deletion or mutation of maternal UBE3A causes Angelman syndrome, whereas duplication of the chromosomal region containing maternal UBE3A is frequently detected in individuals with autism 9, 10 .
Intriguingly, mutations in topoisomerases were recently identified in some individuals with ASD 11, 12 . However, precisely how topoisomerases regulate the expression of Ube3a and possibly other genes associated with autism is unknown. Topoisomerases, including Top1 and Top2b, are expressed throughout the developing and adult mouse brain 13, 14 . Topoisomerases are integral to gene expression, as they resolve DNA supercoiling that is generated during transcription [15] [16] [17] [18] .
Here we sought to determine whether topoisomerases preferentially regulate the expression of additional imprinted genes in neurons, or whether they have broader effects on gene expression. Using genomewide approaches, we unexpectedly found that topoisomerases facilitate the expression of long genes, including numerous long genes associated with synaptic function and ASD. In addition, our study uncovers a transcriptional mechanism that is particularly important for maintaining the expression of numerous ASD genes at normal levels.
Gene length effects
To determine whether topotecan, a TOP1 inhibitor, altered the expression of imprinted genes, we treated cultured cortical neurons from C57BL/6J (B6) 3 CASTEi/J (CAST) F 1 hybrid mice with vehicle or 300 nM topotecan, then used high-throughput transcriptome sequencing (RNA-seq) to survey changes in gene expression genome-wide. Single nucleotide polymorphisms were used to determine the parentof-origin of sequence reads for autosomal genes 19 . We defined imprinted genes as those displaying statistically significant parent-of-origin expression bias in reciprocal B6 3 CAST crosses (Fisher's exact test, P , 0.05 after adjustment for multiple comparisons). We found that cortical neurons expressed 49 known autosomal imprinted genes (Extended Data Table 1), but Ube3a was the only imprinted gene that showed a significant change in parental allele bias in reciprocal crosses upon topotecan treatment (Fisher's exact test, P , 0.05 after correction; Extended Data Table 1 ). Indeed, topotecan increased expression of the paternal allele of Ube3a, driving Ube3a levels significantly above wild-type levels (Extended Data Fig. 1a, b ).
As we found previously 7 , topotecan reduced the expression of an extremely long (.1 megabase), paternally expressed antisense transcript that overlaps Ube3a (Ube3a-ATS; Extended Data Fig. 1a, b ). The Ube3a-ATS transcript is required for paternal Ube3a silencing 20, 21 . Other imprinted genes in the same genomic region as Ube3a did not show changes in allelic expression following topotecan treatment (Extended Data Fig. 1b and Extended Data Table 1) . Notably, topotecan also reduced the expression of UBE3A-ATS and increased the expression of UBE3A in induced pluripotent stem cell (iPSC)-derived neurons from an Angelman syndrome patient (Extended Data Fig. 1c ). Topotecan thus had similar transcriptional effects at the Ube3a locus in mouse and human neurons.
Because Ube3a-ATS is extremely long and was strongly downregulated, we hypothesized that topotecan might reduce the expression of other long genes. Notably, using RNA-seq and Affymetrix microarrays to quantify gene expression, we found that topotecan reduced the expression of nearly all extremely long genes in mouse cortical neurons ( Fig. 1a-c) , with a strong correlation between gene length and reduced expression (for genes longer than 67 kilobases (kb); Pearson's correlation coefficient (R) 5 20.69). Topotecan also reduced the expression of long genes in iPSC-derived human neurons ( Fig. 1d ). Topotecan did not exclusively reduce the expression of extremely long genes, but instead acted over a continuum of gene lengths ( Fig. 1c ). Specifically, the percentage of genes that were inhibited (to any extent) by 300 nM topotecan increased from 50% for genes 67 kb in length to nearly 100% for genes ,200 kb and longer. In addition, inhibition of long genes by topotecan was highly dose dependent (Extended Data Fig. 2 ).
By contrast, topotecan increased the expression of most of the genes that were ,67 kb in length ( Fig. 1c ), although the magnitude of this increase was very small for most genes (Fig. 1a, b ). For some genes, this increase may reflect regulation by longer overlapping transcripts, like for Ube3a, or it might reflect other stimulatory effects of topoisomerase inhibitors 22, 23 .
The length-dependent effects on gene expression were not due to cell death or persistent DNA damage, as topotecan (300 nM for 3 days) did not kill neurons or damage DNA (Extended Data Fig. 3a, b ). Moreover, agents that damage DNA in neurons (paraquat and H 2 O 2 ) did not reduce the expression of long genes (Extended Data Fig. 3b-d) .
Notably, all length-dependent effects were fully reversible upon drug washout (Extended Data Fig. 3e ), ruling out the possibility that gene expression changes were due to permanent effects (such as irreversible DNA damage and/or killing neurons).
A different TOP1 inhibitor, irinotecan, had a highly correlated length-dependent effect on gene expression in cortical neurons (Extended Data Fig. 4 ). In addition, we re-analysed published data from other laboratories and found that irinotecan and camptothecin (another TOP1 inhibitor) strongly reduced the expression of long genes and moderately increased the expression of shorter genes in several human cell lines (Extended Data Fig. 5a-e ). Thus, the length-dependent effects we observed were not unique to postmitotic neurons and could be reproducibly detected in expression data acquired by other laboratories.
We found that lentiviral delivery of short hairpin RNA (shRNA) to knockdown Top1 also reduced the expression of long genes in neurons ( Fig. 2a, c) , providing independent genetic support that TOP1 facilitates the expression of long genes. These gene knockdown results also rule out the possibility that TOP1-DNA covalent complexes, which form only in the presence of TOP1 inhibitors 18 , block the expression of long genes. Unlike TOP1 inhibitors ( Fig. 1a -c and Extended Data Figs 4a and 5a-e), Top1 knockdown did not globally increase the expression of shorter genes ( Fig. 2c ). Thus TOP1 inhibitors probably increase the expression of shorter genes through a drug-specific effect that is unrelated to TOP1 depletion.
TOP2 enzymes (particularly TOP2B) also participate in gene transcription 15, 16, 24 . We next tested whether genetic or pharmacological inhibition of TOP2 enzymes could reduce the expression of long genes. Indeed, with new experiments and by re-analysing data from others 14, 25 , we found that the TOP2A/TOP2B inhibitor ICRF-193 reduced gene expression in a length-dependent manner in cultured mouse cortical neurons, embryonic stem (ES) cells and ES-cell-derived neurons (Extended Data Figs 6a and 7a, b). There was extensive overlap between genes affected by ICRF-193 and topotecan in cortical neurons, particularly for long genes, and the magnitudes of these effects were highly correlated (Extended Data Fig. 6b-e ). Thus, TOP1 and TOP2 enzymes regulate the expression of many of the same genes.
Top2b is the predominant TOP2 expressed in neurons 25 . We next knocked down Top2b with shRNA ( Fig. 2b, d ) and found that this manipulation reduced the expression of long genes ( Fig. 2d ). Moreover, re-analysis of published data sets showed that expression of long genes was reduced in embryonic brain and ES-cell-derived neurons from Top2b 2/2 mice 14 (Extended Data Fig. 7c , f, g). By contrast, long genes were expressed normally in Top2b 2/2 ES cells and neuronal progenitors 25 (Extended Data Fig. 7d , e), presumably because these cell types express Top2a in addition to Top2b 25 . Last, two additional TOP2 inhibitors (doxorubicin and etoposide) reduced the expression of long genes in a human cancer cell line 26 (Extended Data Fig. 5f , g). Together, our data show that TOP1 and TOP2 enzymes are required for proper expression of long genes in mammalian cells. This stands in contrast to yeast, in 
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which length-dependent transcriptional effects specific to Top2 were observed 27 .
Length-dependent effect on elongation
Topoisomerases interact directly with RNA polymerase II (Pol II) and are required for transcription elongation 17, 28, 29 . To study genomewide effects of topotecan on transcription in neurons, we measured Pol II distribution by chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-seq). We calculated the travelling ratio for all genes bound by Pol II, defined as the ratio of Pol II density (read counts per million mapped reads) near transcription start sites to Pol II density in the body of the gene, a parameter that is increased when transcription elongation is inhibited [30] [31] [32] . We found that topotecan produced a distinct length-dependent increase in travelling ratio for very long genes, consistent with an impairment of transcription elongation ( Fig. 3a and Extended Data Fig. 8 ). The change in travelling ratio observed with topotecan treatment could reflect either a progressive inhibition of Pol II as it transcribes long genes, or it could reflect a block in the transition to productive elongation. To distinguish between these possibilities, we examined the change in Pol II density across the entire length of genes at high resolution (Fig. 3b ). We found that Pol II density was slightly increased throughout the gene bodies of smaller genes, consistent with the modest increase in expression seen for smaller genes and with studies showing that TOP1 inhibitors can stimulate the transition to elongation of two genes (both shorter than 67 kb) 5,6 . However, for longer genes, topotecan strongly reduced Pol II density across the entire length of the gene body (Fig. 3b ). These results are consistent with topotecan affecting the transition to productive elongation at long genes. On average, all genes showed a slight increase in Pol II density in the promoter-proximal region (Fig. 3c ) and a stronger increase in Pol II density near the transcription termination site (Fig. 3b ). However, these changes were independent of length, making it unlikely that they contributed to differential expression of short versus long genes. TOP1 inhibitors can stimulate the release of the positive elongation factor P-TEFb 17 . Thus, we next tested whether P-TEFb inhibition would affect expression of longer genes differently from shorter genes by treating neurons with 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB; a P-TEFb inhibitor that can block the transition to elongation 17, 30 ). We found that DRB (100 mM) reduced gene expression equally across all gene lengths ( Fig. 3d ), suggesting that the requirement for P-TEFb is not influenced by length. (Note that 1 mM and 10 mM DRB had no length-dependent effects on expression (data not shown), ruling out the possibility that lower DRB concentrations preferentially impair expression of longer genes.)
Numerous long ASD genes affected
To investigate further the biological consequences of TOP1 inhibition in neurons, we defined a list of genes that were differentially expressed with high confidence. From our RNA-seq expression data, we found that topotecan significantly downregulated 155 genes and significantly upregulated 28 genes (Benjamini-Hochberg method, 5% false discovery rate) ( Supplementary Data 1) . The topotecan-downregulated genes were significantly longer (mean 591 kb, median 548 kb) than all expressed genes in cortical neurons (mean 59.3 kb, median 23.5 kb) and were significantly longer than topotecan-upregulated genes (mean 29.3 kb, median 16.4 kb) (one-way analysis of variance versus all expressed genes P 5 2.2 3 10 216 , versus upregulated genes P 5 3.7 3 10 214 ), further indicating that topotecan has pronounced effects on long genes.
On the basis of Gene Ontology and functional annotation terms, we found that many topotecan-downregulated genes were involved in neuronal development and synaptic function (Supplementary Data 2). Because ASD is thought to be a neurodevelopmental disorder that affects synapses, we cross-referenced our list of downregulated genes with known ASD candidate genes, combining genes in the SFARI Gene database with candidates identified in recent exome sequencing studies 11, 12, [33] [34] [35] (Supplementary Data 3) . Notably, 27% (n 5 49) of the 183 differentially expressed genes are known ASD candidate genes (Table 1 and Supplementary Data 3), a proportion that is highly significant compared to chance (P 5 4.4 3 10 28 , Fisher's exact test). Independent microarray experiments showed that these ASD genes were dose-dependently downregulated by topotecan (Extended Data Fig. 9 ). Notably, ASD candidate genes are exceptionally long as a group; genes in the SFARI Gene database (as of June 20, 2013) are 3.7-fold longer on average than all genes expressed in cortical neurons (means of 217.3 kb versus 59.3 kb). Thus, mutations that alter topoisomerase activity might reduce expression of numerous long ASD genes and might contribute significantly to ASD. Consistent with this hypothesis, recent sequencing studies of autism patient cohorts uncovered rare de novo missense mutations in TOP1, TOP3B, TOPORS (a TOP1-SUMO ligase 36 ) and several other genes that directly connect to TOP1 11, 12 .
Discussion
Our study shows that topoisomerases facilitate the expression of a large number of ASD candidate genes, including many that are long and that are thought to have large effects on ASD pathology in isolation 1,2,37 . Pharmacological inhibition of topoisomerases also reduced expression of long genes in other cell types, suggesting that this length-dependent transcriptional effect is fundamental to all mammalian cells. Our data rule out numerous possibilities as to why topoisomerase inhibitors reduce the expression of long genes (for example, cell death, DNA damage, formation of covalent complexes), and instead implicate a gene-length-dependent block in transcription elongation. Pol II and topoisomerases dynamically form and remodel large supercoiling domains 38 , and the effects of topoisomerases on gene expression are strongly influenced by genomic structure and context 23, 39 . Thus, we speculate that higher order structure differentially constrains shorter and longer genes, and that this creates distinct length-dependent requirements for topoisomerases in transcription elongation. 
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Some long genes were not strongly reduced in expression following topotecan treatment (Fig. 1a) . In many cases this reflected ambiguity in gene annotation (data not shown). For example, a number of long genes also express shorter transcripts, making it difficult to distinguish expression of short isoforms from long isoforms. Alternatively, some long genes might be located within genomic regions that are more permissive for expression when TOP1 is inhibited.
Intriguingly, numerous genes associated with transcription are mutated in autism patients 11, 40, 41 , although how these diverse transcriptional regulators contribute to autism is unclear. Our study highlights a mechanistic link between a critical step in transcription elongation and expression of numerous long ASD candidate genes. Our data suggest that chemicals or genetic mutations that impair topoisomerases, and possibly other components of the transcription elongation machinery that interface with topoisomerases, have the potential to profoundly affect the expression of long ASD candidate genes. Length-dependent impairment of gene transcription, particularly in neurons and during critical periods of brain development, may thus represent a unifying cause of pathology in many individuals with ASD and other neurodevelopmental disorders.
METHODS SUMMARY
All procedures using vertebrate animals were approved by the University of North Carolina Institutional Animal Care and Use Committee. Embryonic (E13.5-15.5) cortical neuron cultures from C57BL/6J 3 CASTEi/J mice (The Jackson Laboratory) were used for RNA-seq and ChIP-seq studies. C57BL/6J mice were used for all other mouse experiments. Cultures were prepared as previously described 7 . Affymetrix Mouse Genome 430 2.0 arrays and Mouse Gene 1.1 ST 24-array plates were used for microarray studies. ChIP-seq experiments were performed essentially as described 30, 42 using RNA Pol II N20 antibody (sc-899, Santa Cruz Biotechnology).
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
Mouse cell culture. Cortical neurons were cultured from E13.5-E15.5 mouse embryos as described 7 . For RNA-seq and ChIP-seq, neurons were seeded on 10-cm diameter poly-D-lysine-treated culture plates at a density of 5-10 3 10 6 per plate. Microarray experiments used 6-well plates seeded at 1 3 10 6 cells per well. After 7 days in culture, drugs or an equivalent amount of vehicle were added and left in the culture medium for 24 or 72 h. For topotecan, irinotecan, DRB and paraquat, vehicle was 0.1% dimethylsulphoxide (DMSO). For ICRF-193, vehicle was 0.02% DMSO.
Lentiviral shRNA experiments used viruses from The RNAi Consortium (acquired from Sigma-Aldrich and from the UNC Lenti-shRNA core): Top1 knockdown used clone TRCN0000011884 (59-CCGGCCAGCGAAGATTCT ATCTTATCTCGAGATAAGATAGAATCTTCGCTGGTTTTT-39) and Top2b knockdown used clone TRCN0000070988 (59-CCGGCCTTGTGTTGTCCTTT GTCTTCTCGAGAAGACAAAGGACAACACAAGGTTTTTG-39). Virus expressing non-targeting hairpin RNA (SHC002, Sigma; 59-CCGGCGTGATCTTCACCG ACAAGATCTCGAGATCTTGTCGGTGAAGATCACGTTTTT-39) was used as a control. Neurons were seeded on 24-well plates at 2 3 10 5 per well. After 3 days in culture, cells were treated with lentivirus at a multiplicity of infection of at least 1. Virus was removed after 24 h, and RNA collected after a further 6 days in culture. Western blotting to assess knockdown was performed with anti-TOP1 (Santa Cruz Biotechnology, H5) or anti-TOP2B (Santa Cruz, H286) antibodies, with signal normalized to b-actin (Millipore, C4).
Cell death was assayed using Sytox Green (Invitrogen Molecular Probes). c-H2AX foci were measured by immunohistochemistry. Primary antibodies were anti-c-H2AX (Millipore, 1:500 dilution) and anti-NeuN (Millipore, 1:500), used to mark neurons. iPSC culture and neuronal differentiation. Human iPSC work was approved by the University of Connecticut Stem Cell Research Oversight Committee. iPSCs that carry a large deletion of maternal 15q11-q13 (AGdel1-0; see also ref. 43 ), this cell line was deemed exempt from IRB approval at the University of Connecticut due to its establishment in 1995 and lack of identifying information) were cultured on irradiated mouse embryonic fibroblasts and manually passaged as described 43 . iPSCs were differentiated into forebrain cortical neurons as described 43 with the following modifications: neural progenitors were generated by culturing iPSCs on feeders in N2B27 medium supplemented with noggin (500 ng ml 21 ) for 8 days and then manually picking neural rosettes for two additional passages using trypsin and standard cell culture protocols. Topotecan was applied to mature neurons and RNA was collected by standard protocols 6 days after the addition of drug or vehicle. qPCR. qRT-PCR was carried out as described 43 using Taqman (Life Technologies) gene expression assays for UBE3A (Hs00166580_m1) and UBE3A-ATS (Hs03454279_m1) according to the manufacturer's instructions. The Taqman assay for GAPDH was used as a control. RNA-seq. Total RNA was collected using Trizol reagent (Invitrogen). Mouse polyA-selected messenger RNA libraries were then prepared using the Illumina True-Seq kit for RNA. For RNA-seq on human-iPSC-derived neuronal samples, stranded multiplexed mRNA libraries were prepared using Illumina kits. Cluster generation and sequencing were performed using the Illumina HiSeq 2000 platform. For allele-specific expression analysis, equal amounts of total RNA from 3-6 biological replicates were pooled before polyA mRNA purification and library preparation.
For non-allelic expression analysis, data from five biological replicates were included. mRNA was isolated and libraries prepared independently for each replicate sample. Library preparation incorporated barcoded adapters and all samples were sequenced in one lane, using 50-base-pair (bp) reads. RNA-seq expression analysis. For allelic expression analysis, informative CAST/B6 SNPs were downloaded from http://www.sanger.ac.uk/resources/mouse/genomes/.
CAST alleles were then substituted into their corresponding mouse reference genome (mm9) positions and sequence reads were aligned to the mm9 and the CAST version of mm9 using Bowtie, selecting for unique matches. Filtered read counts for autosomal genes were tested for allelic bias using Fisher's exact test against a background model derived from autosomes, and P values adjusted for multiple comparisons using the Benjamini-Hochberg procedure. Statistical analysis was performed using R. Genomic intervals were derived from UCSC known genes or created manually where annotation was absent, namely for Ube3a-ATS.
For non-allelic analysis, reads were aligned to mm9 using Bowtie. Read counts were obtained using DEGseq, and normalization and analysis of differential gene expression was performed using the R package, edgeR, using a negative binomial model. 
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